Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jcmm.12635 http://scihub22266oqcxt.onion/10.1111/jcmm.12635 C4594675!4594675!26171944     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Cell+Mol+Med 2015 ; 19 (10): 2329-40 Nephropedia Template TP {{tp|p=26171944|t=2015. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod |pdf=|usr=}}{{26171944}} gab.com Text The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod JO: J Cell Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=26171944 #FOAvip Almost all drugs approved for use in humans possess potentially beneficial ?off-target? effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing FTY720 (also known as fingolimod, Gilenya?), an immunomodulatory drug recently approved for the treatment of multiple sclerosis (MS). The therapeutic benefit of FTY720 in MS is largely attributed to the immunosuppressive effects that result from its modulation of sphingosine 1-phosphate receptor signalling. However, this drug has also been shown to inhibit other cancer-associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti-cancer agent both in vitro and in vivo. Here, we review the effects of FTY720 on signal transduction pathways and cancer-related cellular processes, and discuss its potential use as an anti-cancer drug. Twit Text FOAVip The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod ????J Cell Mol Med http://www.kidney.de/pget.php?&tw=1&pmid=26171944 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26171944 #FOAvip English Wikipedia <ref>{{Cite pmid|26171944}}</ref> The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod #MMPMID26171944 Patmanathan SN; Yap LF; Murray PG; Paterson IC J Cell Mol Med 2015[Oct]; 19 (10): 2329-40 PMID26171944show ga Almost all drugs approved for use in humans possess potentially beneficial ?off-target? effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing FTY720 (also known as fingolimod, Gilenya?), an immunomodulatory drug recently approved for the treatment of multiple sclerosis (MS). The therapeutic benefit of FTY720 in MS is largely attributed to the immunosuppressive effects that result from its modulation of sphingosine 1-phosphate receptor signalling. However, this drug has also been shown to inhibit other cancer-associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti-cancer agent both in vitro and in vivo. Here, we review the effects of FTY720 on signal transduction pathways and cancer-related cellular processes, and discuss its potential use as an anti-cancer drug. äThe antineoplastic properties of FTY720: evidence for the repurposing (epmc).pdf DeepDyve Pubget Overpricing